A
Anjali Zarkar
Researcher at University Hospitals Birmingham NHS Foundation Trust
Publications - 35
Citations - 1998
Anjali Zarkar is an academic researcher from University Hospitals Birmingham NHS Foundation Trust. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 9, co-authored 26 publications receiving 1384 citations. Previous affiliations of Anjali Zarkar include National Health Service & Queen Elizabeth Hospital Birmingham.
Papers
More filters
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Noel W. Clarke,Adnan Ali,F.C. Ingleby,Alex Hoyle,Claire Amos,Gerhardt Attard,Christopher D. Brawley,J. Calvert,Simon Chowdhury,Adrian Cook,William Cross,David P. Dearnaley,Hassan Douis,Duncan C. Gilbert,Silke Gillessen,Robert Jones,Ruth E Langley,Archie Macnair,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,Chris Parker,A.W.S. Ritchie,H. Rush,J.M. Russell,Janet E. Brown,Sharon Beesley,Alison Birtle,L. Capaldi,Joanna Gale,Stephanie Gibbs,Anna Lydon,A. Nikapota,Aurelius Omlin,Joe M O'Sullivan,Omi Parikh,Andrew Protheroe,S. Rudman,Narayanan Srihari,Matthew S. Simms,Jacob Tanguay,Shaun Tolan,John Wagstaff,Jan Wallace,James D. Wylie,Anjali Zarkar,Matthew R. Sydes,Mona Parmar,Nicholas D. James +49 more
TL;DR: The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden.
Journal ArticleDOI
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Chris Parker,Noel W. Clarke,Adrian Cook,Howard Kynaston,Peter Meidahl Petersen,Charles Catton,William Cross,John P Logue,Wendy R. Parulekar,Heather Payne,Rajendra Persad,Holly Pickering,Fred Saad,Juliette Anderson,Amit Bahl,David Bottomley,Klaus Brasso,Rohit Chahal,Peter Cooke,Ben Eddy,Stephanie Gibbs,Chee Goh,Sandeep Gujral,Catherine Heath,Alastair Henderson,Ramasamy Jaganathan,Henrik Jakobsen,Nicholas D. James,S.K. Sundaram,Kathryn Lees,Jason F. Lester,Henriette Lindberg,Julian Money-Kyrle,S L Morris,Joe M. O'Sullivan,Peter Ostler,Lisa Owen,Prashant Patel,Alvan Pope,Alvan Pope,Alvan Pope,Rick Popert,Rakesh Raman,Martin Andreas Røder,Ian Sayers,Matthew S. Simms,James M. Wilson,Anjali Zarkar,Mahesh K. B. Parmar,Matthew R. Sydes +49 more
TL;DR: The initial results do not support routine administration of adjuvant radiotherapy after radical prostatectomy, and an observation policy with salvage radiotherapy for PSA biochemical progression should be the current standard after radical Prostate cancer.
Journal ArticleDOI
Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.
V. Harris,John Staffurth,O. Naismith,Alikhan Esmail,Sarah L. Gulliford,Vincent Khoo,Rebecca Lewis,John Littler,Helen McNair,Azmat Sadoyze,Christopher D Scrase,Aslam Sohaib,Isabel Syndikus,Anjali Zarkar,Emma Hall,David P. Dearnaley +15 more
TL;DR: Modifications to the RTOG technique are proposed, including the addition of a 3-mm BEM, which resulted in LN-CTV coverage similar to that of the RMH technique, with reduction in bowel and planning target volume overlap.
Journal ArticleDOI
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
Syed A. Hussain,Deborah D. Stocken,D. R. Peake,John Glaholm,Anjali Zarkar,D. M. A. Wallace,Nicholas D. James +6 more
TL;DR: Organ preservation using multimodality therapy is feasible and safe, even in patients with poor renal reserve, and does not compromise salvage therapies.